

HERANBA
 CIN: L24231GJ1992PLC017315
 Reg. Off: Plot No. 150/1/505/150/1 GIDC, Phase-II, Vaidad, Vapi - 396195, Gujarat, India
 Cor. Off: 2nd Floor, A-Wing, Fortune Avirah, Jain Desaru Road, Borivali-West, Mumbai - 400092, Maharashtra, India
 Website: www.heranba.co.in; Email: compliance@heranba.com

NOTICE
 Pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 (as amended from time to time), Notice is hereby given that a meeting of the Board of Directors of Heranba Industries Limited, will be held on Friday, May 23, 2025, to consider and approve inter-alia the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2025. Further, we wish to inform that the company's Trading Window for dealing in securities of the company by Designated Person(s) has already been closed with effect from April 01, 2025 and will remain closed till 48 hours from the declaration of Audited Standalone and Consolidated Financial Results on this, the investors may visit the Company's website For further Information/updates on this, the investors may visit the Company's website www.heranba.co.in and Stock Exchange's website at www.bseindia.com and www.nseindia.com

For Heranba Industries Limited
 CS Abdul Latif
 Company Secretary & Compliance Officer
 Membership No.: A17009
 Place : Mumbai
 Date: 16-05-2025

FORM B
INVITATION FOR EXPRESSION OF INTEREST FOR
PRIMAT INFRAPOWER & MULTIVENTURES PRIVATE LIMITED,
OPERATING IN VARIOUS FINANCIAL SERVICES AT LOWER PAREL, MUMBAI
 (Under sub-regulation (1) of regulation 36A of the Insolvency and Bankruptcy Code of India (Insolvency Resolution Process for Corporate Persons) Regulations, 2016)

Sr.	RELEVANT PARTICULARS
1.	Name of the corporate debtor along with PAN & CIN/LLP No. Primat Infropower & Multiventures Private Limited CIN: U74110MH1999PTC285503
2.	Address of the registered office 18th Floor, A Wing, Marathon Futures, N. M. Joshi Marg, Lower Parel, Mumbai City, Mumbai, Maharashtra, India, 400013 https://www.primat.com/
3.	URL of website No Tangible fixed assets
4.	Details of place where majority of fixed assets are located Non-Operating (ceased its operations since FY 2020-21)
5.	Installed capacity of main products/services Non-Operating (ceased its operations since FY 2020-21)
6.	Quantity and value of main products/services sold in last financial year Not available/Zero
7.	Number of employees/workmen Last available audited financial statements are for FY 2023-24. Further details are available at: https://www.primat.com/
8.	Further details including last available financial statements (with schedules) of two years, lists of creditors are available at URL: Any eligibility criteria for EDI would be over and above the qualification criteria specified under section 25A(2)(h) of the Code.
9.	Eligibility for resolution applicants under section 25(2)(h) of the Code is available at URL: 02-06-2025 (Sunday)
10.	Last date for receipt of expression of interest 02-06-2025 (Monday)
11.	Date of issue of provisional list of prospective resolution applicants 07-06-2025 (Saturday)
12.	Last date for submission of objections to provisional list 07-06-2025 (Saturday)
13.	Date of issue of final list of prospective resolution applicants 07-06-2025 (Saturday)
14.	Date of issue of information memorandum, evaluation matrix and request for resolution plans to prospective resolution applicants 07-07-2025 (Monday)
15.	Last date for submission of resolution plans Process email ID to submit: primat.cip@gmail.com
16.	Process email ID to submit Expression of Interest Not Registered
17.	Details of the corporate debtor's registration status as MSME. Not Registered

Please note that this publication of Form-B is subject to the approval from Hon'ble NCLT towards extension and auction.

CA IP Sachin Sarthava Bhattacharya
 Authorized Director
 Stress Credit Resolution Private Limited
 Resolution Professional
 Primat Infropower & Multiventures Private Limited
 Reg No: IBBI/RPE/CO94/IPA/3/2023-24/50059
 Regd. Add. with IBBI: B-1305/16, Dosti Elite, Road No. 29, San Easti, Mumbai - 22
 AFA valid up to 31.12.2025

Date: 17-05-2025
 Place: Mumbai

SUDARSHAN PHARMA INDUSTRIES LIMITED
 Reg. office: 301, Aura Bldg, Plot no. 7, Above Kalyan Jewellers, S. V. Road, Borivali (W), Mumbai 400022.
 CIN: L51499AH2009PLC184967 Tel: 022 - 4222 1111
 Website: www.sudarshanpharma.com Email: compliance@sudarshanpharma.com

NOTICE OF EXTRA ORDINARY GENERAL MEETING
 Members are requested to note that pursuant to and in compliance with the provisions of Section 110 and all other applicable provisions, if any, of the Companies Act, 2013 read with the applicable Rules framed thereunder including Rule 20 and Rule 22 of the Companies (Management and Administration) Rules, 2014 (including any statutory amendments), modification(s) or re-structure(s) thereof for the time being in force) (the "Act"), General Circular no. 9/2024 dated September 19, 2024 and the previous circulars on COVID-19 related relaxations issued by Ministry of Corporate Affairs (MCA) applicable in the regard (the "MCA Circulars"), Regulation 44 of the Securities and Exchange Board of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") and all other applicable laws, rules and regulations, if any, the Company has sent the Notice of the EGM on 16th May, 2025, through electronic mode only, to those members whose e-mail addresses are registered with the Company / Registrar and Transfer Agent (RTA), Kfin Technologies Limited ("KfinTech") / Depositories.

Sr. No.	Description of Special Business
1.	Authority to create charges, mortgages, hypothecations and other encumbrances under Section 180(1)(a) upto an amount not exceeding Rs 2500 Crores
2.	Authority to borrow from time to time, any sum or sums of monies under Section 180(1)(c) upto an amount not exceeding Rs 2500 Crores
3.	Approval of Related Party Transactions with Sudarshan Pharma Industries Private Limited, Singapore, wholly-owned subsidiary of the Company
4.	Approval of Related Party Transactions with Raina Lifesciences Private Limited, wholly-owned subsidiary of the Company
5.	Approval of Related Party Transactions with Ishwah Healthcare Private Limited, subsidiary of the Company
6.	Approval of Related Party Transactions with Sudarshan Moven Pharma Private Limited, subsidiary of the Company
7.	Approval of Related Party Transactions with Life Science Chemical Private Limited, wholly-owned subsidiary of the Company
8.	Approval of Related Party Transactions with Sudarshan Pharma Lifescience Private Limited, wholly-owned subsidiary of the Company
9.	Approval of Related Party Transactions with Sudarshan Solvents Industries Limited, related party
10.	Approval of Related Party Transactions with Sachin Chemicals Industry Private Limited, related party
11.	Approval of Related Party Transactions with Sudarshan Capital Private Limited, related party
12.	Approval of Related Party Transactions with Magconchem Private Limited, related party
13.	Approval of Related Party Transactions with Sudarshan Chempharma India LLP, related party
14.	Approval of Related Party Transactions with Sudarshan Ashar Specialty Chemicals LLP, related party
15.	Approval of Related Party Transactions with M/s. Sachin Chemicals, related party

In compliance with the MCA Circulars, the Company has completed the dispatch of Notice on Friday, 16th May, 2025 by electronic mode to the Members of the Company holding shares as on Friday, 9th May 2025 and whose email addresses are registered with the Company / Depository(s) / Depository Participants / Registrar and Transfer Agent - KfinTech.

Notice together with explanatory statement and instruction for E-voting is available on the website of the Company at www.sudarshanpharma.com, on the website of BSE Limited at www.bseindia.com and on the website of National Securities Depository Limited ("NSDL") at www.evoting.nsdl.com

The voting rights of members shall be in proportion to the equity shares held by them in the paid-up equity share capital of the Company as of the cut-off date i.e. Thursday, 9th June, 2025 ("Cut-off date"). The remote e-voting period commences on Monday, 9th June, 2025 at 9:00 a.m. IST and ends on Wednesday, 11th June, 2025 at 5:00 p.m. IST. Thereafter, the remote e-voting module shall be disabled for voting by NSDL.

Members whose email address are not registered with Depository Participants (in case of shares held in electronic / dematerialized mode) or with KfinTech (in case of shares held in physical mode) hold shares as on Cut-off date can cast their vote on resolutions proposed in the Notice through E-voting, by following the instructions given in the Notice to the Notice under "Using through E-Voting" or can contact the Company at compliance@sudarshanpharma.com

Members who have not registered / updated their email address(es), are requested to get the same registered / updated with the Company (in case of shares held in physical mode) by writing to the Company at compliance@sudarshanpharma.com along with details of folio number, scanned copy of share certificate (front and back) and self-attested copy of PAN card (front and back) or with their Depository Participants (in case of shares held in electronic / dematerialized mode) with whom they maintain their demat accounts.

Details of persons contacted for any issues / queries / grievances relating to E-voting:
 NSDL:
 Members may refer to the Frequently Asked Questions ("FAQs") and e-voting user manual available at www.evoting.nsdl.com, under "Help" section or send an email to evoting@nsdl.com
 Company:
 Mr. Niren Shah, Company Secretary & Compliance Officer at 301, Aura Bldg, Plot no. 7, Above Kalyan Jewellers, S. V. Road, Borivali (West), Mumbai - 400092 or send an email at compliance@sudarshanpharma.com or call at 022 - 4222 1111.


By Order of the Board of Directors
 For, Sudarshan Pharma Industries Limited
 Sd/-
 Sachin Mehta
 Joint Managing Director
 DIN: 02211178
 Date: 16th May 2025
 Place: Mumbai

DUNCAN ENGINEERING LIMITED
 Regd. Office : F-33, Rajangaon MIDC, Karegaon, Tal-Shirur, Dist. Pune - 412220, CIN: L28991PN1961PLC139151
 Tel : + 91-2138-660066, Website: www.duncanengg.com, Email ID: complianceofficer@duncanengg.com

AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2025

Based on the recommendations of the Audit Committee, the Board of Directors of Duncan Engineering Limited ("the Company") at its meeting dated May 16, 2025, has approved the Audited Financial Results for the quarter and year ended March 31, 2025, in terms of Regulation 33 of SEBI (Listing Obligations & Disclosures Requirements) Regulations, 2015.

The aforesaid Financial Results along with the Audit Report of the Statutory Auditors of the Company (S S Kothari Mehta & Co. LLP) thereon are available at https://duncanengg.com/investors_details/board-meeting-notice-and-outcome and can also be accessed by scanning a Quick Response Code given below:



Scan the QR Code to view the Results on the Website of the Company

For Duncan Engineering Limited
 Akshat Goenka
 Managing Director
 DIN: 07131982
 Date: 16.05.2025
 Place: Noida

GIC HOUSING FINANCE LTD.
 YOUR ROAD TO A DREAM HOME
 CIN : L65922MH1989PLC054583
 Regd. Office : 6th Floor, National Insurance Building, 14, Jamshedji Tata Road, Churchgate, Mumbai - 400 020. | Website: www.gicfhindia.com

STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2025

Sr. No	PARTICULARS	(₹ in Lakh)			
		Quarter Ended (31/03/2025) (Audited)	Quarter Ended (31/03/2024) (Audited)	Year to Date (31/03/2025) (Audited)	Previous Year Ended (31/03/2024) (Audited)
1	Total Income from operations	27,581	26,553	1,08,888	1,06,964
2	Net Profit/(Loss) for the period (before tax, Exceptional and/or Extraordinary items)	6,854	7,910	21,943	20,391
3	Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary Items)	5,548	7,910	20,637	20,391
4	Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary Items)	3,509	5,359	16,017	15,116
5	Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax))	3,483	5,415	15,999	15,357
6	Paid up Equity Share Capital (Face value ₹ 10/-)	5,385	5,385	5,385	5,385
7	Reserves as at 31st March (Audited)	1,91,053	1,77,477	1,91,053	1,77,477
8	Securities Premium Account	11,699	11,699	11,699	11,699
9	Net Worth (Audited)	1,96,441	1,82,865	1,96,441	1,82,865
10	Paid up Debt capital/Outstanding Debt	8,72,731	8,56,329	8,72,731	8,56,329
11	Outstanding Redeemable Preference Shares	-	-	-	-
12	Debt Equity Ratio	4.44	4.68	4.44	4.68
13	Earning Per Share (EPS) on Face Value ₹ 10/-	(a) Basic 6.52	6.52	9.95	9.95
	(b) Diluted	6.52	6.52	9.95	9.95
14	Capital Redemption Reserve	Not Annualised	Not Annualised	Annualised	Annualised
15	Debtenture Redemption Reserve	-	-	-	-
16	Debt Service Coverage Ratio	Not Applicable	Not Applicable	Not Applicable	Not Applicable
17	Interest Service Coverage Ratio	Not Applicable	Not Applicable	Not Applicable	Not Applicable



